News | May 25, 2026
SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth
Revenue from operations climbed 13% to Rs. 886.87 crore
Revenue from operations climbed 13% to Rs. 886.87 crore
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Surya to lead medical governance, patient safety, clinical excellence, and quality assurance initiatives across the organization’s pan-India network.
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
The approval was granted by Agenzia Italiana del Farmaco
Subscribe To Our Newsletter & Stay Updated
